DYNAVAX TECHNOLOGIES CORP

DVAX

Explore Our Financial Data > Companies > DYNAVAX TECHNOLOGIES CORP
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
DVAX
CIK0001029142
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608
Website dynavax.com
Phone5108485100
CEORyan Spencer
Employees350

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$330.51 million
Pre-Tax Income$-40.61 million
Net Income$-43.40 million
Net Income to Common$-43.40 million
EPS$-0.35
View All
Balance Sheet
Cash$160.25 million
Assets$946.51 million
Liabilities$412.37 million
Common Equity$534.14 million
Liabilities & Equity$946.51 million
View All
Cash Flow Statement
Net Income$-43.40 million
Cash From Operating Activities$90.63 million
Cash From Investing Activities$152.39 million
Cash From Financing Activities$-202.74 million
Change in Cash$40.94 million
View All
Calculations
NOPAT$7.31 million
EBITDA$11.81 million
Price to EarningsN/A
Price to Book$3.41
ROE-7.14%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Sanofi Buyout Ends Dynavax Listing And Shifts Vaccine Upside To Group

Sanofi has completed its acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX), closing the transaction and changing the company’s ownership structure. Following the deal, Dynavax has been delisted from Nasdaq and removed from major stock indices, ending its status as a publicly traded company. The acquisition triggered broad changes to Dynavax’s board and executive leadership team, reshaping corporate governance. Dynavax, known for its work in vaccines and immunology, now sits...

Article Link

A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates

Dynavax Technologies stock overview Dynavax Technologies (DVAX) has been drawing attention from investors primarily for its role as a commercial stage vaccine producer, with products and candidates spanning hepatitis B, plague and shingles, as well as multiple public sector collaborations. See our latest analysis for Dynavax Technologies. At a share price of $15.50, Dynavax Technologies has mostly moved sideways in the very short term. However, a 90 day share price return of 37.66% and 1 year...

Article Link

Is It Time To Reassess Dynavax (DVAX) After The Agreed Sanofi Cash Acquisition Deal

If you are looking at Dynavax Technologies and wondering whether the current share price reflects its true worth, this article will walk you through what the numbers actually say about value. The stock closed at US$15.50 recently, with returns of 0.1% over 7 days, 0.6% over 30 days, 0.8% year to date, 22.0% over 1 year, 36.7% over 3 years and 58.5% over 5 years, which may have some investors reassessing both upside potential and risk. Recent news coverage around Dynavax has focused on its...

Article Link

Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects. Th

Article Link

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:

Article Link